GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 250 Note 52 : Segment Reporting An operating segment is one whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance. The Group has identified the Chief Operating Decision Maker as its Managing Director. The Chief Operating Decision Maker reviews performance of pharmaceutical business on an overall basis. As the Group has a single reportable segment, the segment wise disclosure requirements of Ind AS 108 on Operating Segment is not applicable. In compliance to the said standard, Entity-Wide disclosures are as under : ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 Revenues from external customers attributed to the country of domicile and attributed to all foreign countries from which the Group derives revenues Revenue from the Country of Domicile- India 3196,13.20 2910,96.87 Revenue from foreign countries 81,89.72 14,63.30 Total 3278,02.92 2925,60.17 ( ` in lakhs ) Year ended March 31, 2022 Year ended March 31, 2021 Details of non current asset Non Current asset from the Country of Domicile- India 611,03.45 796,79.15 Non Current asset from foreign countries - - Total 611,03.45 796,79.15 Information about major customers The Group did not have any external revenue from a particular customer which exceeded 10% of total revenue. Note 53 : Related Party Disclosures Related party disclosures, as required by IND AS 24, “Related Party Disclosures”, notified under Section 133 of the Companies Act, 2013 are given below: 1 Relationships (during the year): (i) Shareholders (the GlaxoSmithKline (GSK) Group shareholding) in the Group : Glaxo Group Limited, U.K. GlaxoSmithKline Pte Limited, Singapore Eskaylab Limited, U.K. Burroughs Wellcome International Limited, U.K. Holding Group / ultimate holding Group of the above shareholders GlaxoSmithKline Plc, U.K. * GlaxoSmithKline Finance Plc, U.K.* Setfirst Ltd, U.K. * SmithKline Beecham Limited, U.K. Wellcome Limited, U.K.* The Wellcome Foundation Limited, U.K.* Wellcome Consumer Healthcare Limited, U.K.* * no transactions during the year